Stay updated on Tuspetinib in AML: Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the Tuspetinib in AML: Safety & Efficacy Clinical Trial page.

Latest updates to the Tuspetinib in AML: Safety & Efficacy Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to study details, eligibility criteria, or locations are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe study Locations sections were updated: new locations were added and existing ones removed, altering the list of recruiting sites. A revision tag (Revision: v3.3.3) was added to the page.SummaryDifference1%

- Check47 days agoChange DetectedRevision: v3.3.2 appears on the page header, replacing the previous Revision: v3.3.1. This is a minor update with no visible changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedA clarifying line stating that publications are automatically filled from PubMed was added to the Publications section, and the footer revision now shows v3.3.1. The previous PubMed note and the old v3.2.0 revision text were removed.SummaryDifference0.1%

- Check61 days agoChange DetectedRemoved the government funding lapse notice and related operating-status information from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check75 days agoChange DetectedNo substantive changes detected between the old and new screenshots of the ClinicalTrials.gov study page; content and structure appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Tuspetinib in AML: Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tuspetinib in AML: Safety & Efficacy Clinical Trial page.